

RESEARCH

Open Access



Twenty-four years of prescription patterns in bipolar disorder inpatients with vs without lithium: a pharmacoepidemiological analysis of 8,707 cases in German-speaking countries

Waldemar Greil^{1,2,10*}, Mateo de Bardeci^{2,3†}, Nadja Nievergelt², Andreas Erfurth^{4,5}, Gregor Hasler⁶, Rene Bridler², Sermin Toto⁷, Renate Grohmann¹, Johanna Seifert⁷ and Georgios Schoretsanitis^{3,8,9}

Abstract

Background Global pharmacoepidemiological evidence suggests dynamically changing prescription patterns in patients with bipolar disorders. We assessed trends in the use of pharmacological agents used in the management of bipolar disorders in inpatients.

Methods We examined drug use data provided by the Drug Safety in Psychiatry Programme AMSP (German: “Arzneimittelsicherheit in der Psychiatrie”), including psychiatric hospitals in Germany, Austria and Switzerland. We included data from adult inpatients with bipolar disorders (ICD-10: F31) treated between 1994 and 2017. We compared prescription patterns between patients receiving therapeutic regimens with vs. without lithium. Patients with manic and depressive episodes were also analyzed separately.

Results We identified a total of 8,707 patients (58% females, mean age 50.8 ± 14.8 years). Our analysis revealed a decrease of lithium use (up to 2004) and a consistent increase of prescription rates for second-generation antipsychotics (SGA) among which quetiapine ($n = 2,677$) and olanzapine ($n = 1,536$) were the most common. Among psychotropic drugs, quetiapine was most frequently combined with lithium ($n = 716$, 25.6%). Lithium-treated patients received a higher number of drugs compared to patients not receiving lithium (mean number of drugs in patients with vs. without lithium 4.99, $n = 2,796$ vs. 4.75, $n = 5,911$, $p = 0.002$). Thyroid therapeutics were given more often, valproate and quetiapine less often in the lithium group. Antidepressants were consistently prescribed to more than 60% of patients with bipolar depressive episodes.

Conclusions Our findings suggest that SGAs are gradually becoming the mainstay treatment option in bipolar disorder, continuously replacing lithium. The use of antidepressants remains concerningly high. We call for action to improve adherence to evidence-based guidelines.

[†]Waldemar Greil and Mateo de Bardeci contributed equally to this work.

*Correspondence:

Waldemar Greil
waldemar.greil@med.uni-muenchen.de; waldemar.greil@gmx.de

Full list of author information is available at the end of the article

Keywords Bipolar disorders, Lithium, Mood stabilizer, Antipsychotics, Antidepressants, Pharmacoepidemiology

Background

Bipolar disorder is a severe mental illness with a substantial global health burden (Ferrari et al. 2016). The pharmacological treatment constitutes a main part of the short- and long-term treatment of bipolar disorder. Guidelines and experts specifically recommend lithium as a first-line treatment option for bipolar disorder (Yatham et al. 2018; Shah et al. 2017; Fiorillo et al. 2023). In particular, lithium should be also considered in treatment of patients suffering from suicidal ideation, as there is consistent data suggesting suicide preventive properties for lithium (Antolin-Concha et al. 2020; Lewitzka et al. 2015). Moreover, evidence suggests that lithium has long-term immunomodulatory effects (Queissner et al. 2020); specifically, lithium-treatment appears to have anti-inflammatory effects, which in turn are associated with slower progression of illness symptoms (Queissner et al. 2020). Parallel to these disease-modifying properties, evidence from lithium treatment in patients with mild cognitive impairment suggest procognitive effects (Forlenza et al. 2011).

Despite these clinical recommendations and the unique clinical benefits of lithium, prescription trends in patients with bipolar disorder demonstrate that these recommendations are not adhered to (Kriner et al. 2024; Greil et al. 2024). Specifically, a concerning decline in lithium use has been observed in different large pharmacoepidemiological studies (Greil et al. 2024; Rhee et al. 2020; Kessing et al. 2016; Chiu et al. 2024; Shuy et al. 2024; Kleimann et al. 2016; Wolfspurger et al. 2007). Over the past decades, lithium has been gradually replaced by second generation antipsychotics, such as olanzapine and quetiapine, and anticonvulsants, including valproate and lamotrigine, in treatment of patients with bipolar disorder (Kessing et al. 2016; Chiu et al. 2024). However, the alternatives to lithium are associated with serious risks, e.g. olanzapine and quetiapine can cause metabolic syndrome, and valproate should generally be avoided in women of childbearing age (Yatham et al. 2018). To overcome the striking gap between guidelines and clinical practice (Kriner et al. 2024; Kessing 2024), there have been efforts calling for action to counter the declining prescription trends of lithium, e.g. psychoeducation (Malhi et al. 2023), as well as reducing common misconceptions around lithium (Fiorillo et al. 2023). One of the main reasons potentially underlying the prescription trends in patients with bipolar disorder may refer to concerns for adverse lithium-induced reactions in the short- and long-term (Greil et al. 2023; Schoretsanitis et al. 2022; Hidalgo-Mazzei et al. 2023). Additionally, the extensive and elaborate blood monitoring protocols may affect the

willingness of patients, but also of clinicians, to initiate lithium over other seemingly low-maintenance treatment options (Hidalgo-Mazzei et al. 2023; Mandal et al. 2019). Such alternative options may include second generation antipsychotics, which are being increasingly prescribed in the treatment of bipolar disorder gradually replacing lithium (Rhee et al. 2020; Chiu et al. 2024). Moreover, the prescription of antidepressant drugs in bipolar patients contrary to recommendations in guidelines reflects a popular treatment choice (Kessing et al. 2016). Nevertheless, pharmacoepidemiological data can help to identify prescription trends. For instance, an Italian population-based study suggested a continuous decline in lithium prescription until 2006, which was subsequently followed by an increase of lithium use in 2010 (Parabiaghi et al. 2015). Similar patterns with increasing lithium prescription rates following early decline were also reported in other large cohorts (Rhee et al. 2020; Shafiq et al. 2023). The incentives underlying such prescription trends are not always easy to elucidate, as they heavily depend on multiple factors, including treatment setting, diagnostic profiles (Shuy et al. 2024), as well as healthcare resources, such as insurance costs and availability of medications and generic drugs (Monteith et al. 2016).

Therefore, it remains essential to provide further prescription data in patients with bipolar disorder. The aim of our study was to investigate drug use patterns in psychiatric inpatients with bipolar disorder over an extensive time period using data from the European drug surveillance programme AMSP (German: “Arzneimittelsicherheit in der Psychiatrie”), additionally comparing the use of drugs in patients suffering from bipolar disorder with and without lithium. Such evidence will not only facilitate the identification of gaps between clinical practice and evidence-based recommendations, but could also provide a foundation to determine if future interventions are necessary.

Methods

The present study analyzed drug use data from the European Drug Safety in Psychiatry (AMSP) Programme (Bridler et al. 2015; Glocker et al. 2023; Seifert et al. 2022), an ongoing multicenter drug safety project in German speaking countries. AMSP gathers data on the use of psychotropic drugs as well as related reports of adverse drug-induced reactions (ADRs) from a trinational network of psychiatric hospitals in Austria, Germany and Switzerland. Collected data includes drug use, age, sex, as well as diagnoses of all inpatients in treatment on two reference days per year in a cross-sectional manner. A detailed description of methods can be found elsewhere

(Bridler et al. 2015; Glocker et al. 2023; Seifert et al. 2022; Grohmann et al. 2004).

Statistics

We classified the prescribed drugs into the following groups antidepressant drugs (AD), antipsychotic drugs (APD), tranquilizing drugs (TRD), hypnotic drugs (HYP), lithium (Li) and anticonvulsant drugs (AC). We included patients between ≥ 18 and < 90 years of age with a primary diagnosis of bipolar disorder (F31 according to International Statistical Classification of Diseases and Related Health Problems, 10th Revision; ICD-10) between 1994 and 2017 (up to 2000 patients were diagnosed by the clinicians according to ICD-9, but classified according to ICD-10 for this study). Patients were allocated to each group based on at least one prescription of a drug from each group for every calendar year from 1994 to 2017. Finally, we calculated the percentages and visualized the results. Given that mood stabilizers are the mainstay of treatment for bipolar disorder (Schoretsanitis and Paulzen 2022), we specifically assessed the prescription patterns of mood stabilizers separately: we investigated the use of second-generation antipsychotics (SGA), mood stabilizers (MS; including lithium and the anticonvulsants carbamazepine, lamotrigine and valproate), lithium, as well as AC (all anticonvulsants) separately.

Combinations with vs. without lithium in patients with bipolar disorder

Further, we aimed to address drug use patterns in patients with vs. without lithium. We also calculated the percentage of psychotropic drugs in patients with vs. without lithium. P-values were determined using chi-square methods.

Diagnostic subtypes

Drug use patterns in patients with depressive episodes (F31.3-5) and manic episodes (ICD-10 F31.0-2) were examined separately.

Table 1 Patients with bipolar disorders with data on prescription patterns between 1994–2017 ICD-10: International Statistical classification of diseases and related health problems 10th revision; SD: standard deviation

Total number of patients	8,707
Age, years (SD)	50.8 (14.8)
Females, n (%)	5,073 (58%)
> 65 years old, n (%)	1,543 (18%)
Diagnostic subgroups (ICD-10)	
Depressive episodes (F31.3-5)	4,023 (46.2)
Manic episodes (F31.0-2)	3,305 (38.0)
Other (F31.6-9)	1,194 (13.7)
No information on subdiagnoses (F31.x)	185 (2.1)

Results

We investigated drug use patterns in 8,707 adult patients (58% females, mean age 50.8 ± 14.8 years, Table 1). The temporal course of prescriptions of SGAs and mood stabilizers (i.e., lithium, valproic acid, lamotrigine, and carbamazepine), lithium (separately) and anticonvulsants between 1994 and 2017 is shown in Fig. 1. The exact number of prescriptions can be found in supplementary Table 1. We found an increase of prescription rates for SGAs (up to about 80%), most commonly quetiapine ($n = 2,677$) and olanzapine ($n = 1,536$; supplementary Table 2). Quetiapine was most frequently combined with lithium ($n = 716$, 25.6%). Quetiapine was used in low doses as follows (up to 25 mg/d: 3.8%, up to 50 mg/d: 11%, up to 75 mg/d: 13% and up to 100 mg/d: 23%), and olanzapine as follows (up 2.5 mg/d: 3.7%, up to 5 mg/d: 17.5% and up to 7.5 mg/d: 22.3%). Lithium use declined from about 45% to about 30% in the study period (stable at this level from 2004 on), while the mood stabilizers (i.e., lithium plus mood stabilizing anticonvulsants) remained largely stable with about 60% throughout the whole study period. Valproic acid was used more frequently in men than in women (approximately 40% versus approximately 30%). Notably, valproate was also used in 20–30% of cases in women aged 40 years and younger, compared with about 40% in men aged ≤ 40 years (see supplementary Fig. S1 a, b, c, d).

Therapeutic regimens with vs. without lithium in patients with bipolar disorder

The temporal course of prescription rates for antipsychotics, anticonvulsants, antidepressants, hypnotics and tranquilizers in patients with ($n = 2,796$; mean age 49 ± 14 years) vs. without lithium ($n = 5,911$; mean age 50 ± 15 years) is shown in Fig. 2a and b (See Table 2).

In the without-lithium group anticonvulsants were used more often, whereas antipsychotics did not differ essentially. A list of the most common drugs combined with lithium is provided in Table 2a, b and in supplementary table 3a, b. Among psychotropic drugs, valproate was more commonly used in the lithium-free group (38% vs. 16%, $p < 0.001$), as was quetiapine, but to a lesser extent (33% vs. 26%, $p < 0.001$). The same applies to lorazepam, lamotrigine, carbamazepine and aripiprazole. Note, in the period 2008–2017 quetiapine use was very high in both groups, without lithium as well as with lithium (47% vs. 38%, $p < 0.001$; supplementary table 3b).

Among somatic medications, thyroid therapeutics were used more often in the lithium vs. without-lithium group (21% vs. 16%, $p < 0.001$, Table 2b). Other groups of somatic medications were given more frequently in the lithium-free versus lithium-treated bipolar patients. Note, antihypertensive agents including beta-blockers, calcium antagonists and angiotensin-converting enzyme




Fig. 1 Use of second-generation antipsychotics (SGA), of lithium, of anticonvulsants (AC), and of mood stabilizers, in patients with bipolar disorders from 1994 to 2017. MS: Mood Stabilizers (lithium, carbamazepine, lamotrigine, valproate). SGA: Second Generation Antipsychotics. Li: Lithium. AC: Anticonvulsant medication

(ACE) inhibitors and other drugs for the treatment of hypertension, were most frequently combined with lithium ($n=763$, 27%). However, these drugs were even more used in the without-lithium group ($n=2081$, 35%, $p<0.001$). Furthermore, statistically significantly more often given in the lithium-free group of patients were gastrointestinal agents, analgetics/ antirheumatics, and diuretic agents (Table 2b).

Patients under lithium were treated with a higher number of drugs (both psychotropic and somatic) compared to those not treated with lithium (mean number of drugs in patients with vs. without lithium 4.99, $n=2796$ vs. 4.75, $n=5911$, $p<0.01$), supplementary Table 4). When considering only use of psychotropic drugs, lithium-treated patients received a higher number of psychotropic drugs (including lithium) compared to patients not treated with lithium (mean number of drugs in patients with vs. without lithium 3.4 vs. 2.9, $p<0.01$). Daily doses of concomitantly used drugs did not differ between patients with vs. without lithium except for lamotrigine, valproate and venlafaxine (with higher median doses in the lithium group; supplementary Table 5). The main difference between lithium and non-lithium treatment is the higher use of anticonvulsant medication (AC).

Prescriptions in different diagnostic groups of patients with bipolar disorder

Patients with depressive episodes (ICD-10 F31.3-5)

The temporal course of prescriptions for lithium, anticonvulsants, antidepressants, antipsychotics, tranquilizers and hypnotics in 4,023 patients (mean age 52.7 ± 14.4 years, 20% are >65 years old, 62% are females) during a depressive episode shown in Fig. 3a, whereas the yearly prescription rates can be found in supplementary Table 6. More than 65% (up to 90%) of patients with bipolar depressive episodes were treated with antidepressants throughout the study period. Lithium use declined from about 50% to about 30% (until 2000) and remained more or less stable in the following years.

Patients with manic episodes (ICD-10 F31.0-2)

The temporal course of prescriptions for lithium, anticonvulsants, antidepressants, antipsychotics, tranquilizers and hypnotics in 3,305 patients (mean age 49.0 ± 15.2 years, 15% are >65 years old, 53% are females) with manic episodes during the study period is shown in Fig. 3b, whereas the yearly prescription rates can be found in supplementary Table 7. Remarkably, the use of lithium declined clearly from 62 to 29% (no essential change from 2004 on). The antipsychotic drugs remained stable at about 80% throughout the study period (see also supplementary Table 7; supplementary Tables 8 and 9 give the exact rates of drugs in all bipolar patients with and without lithium). The comparison of manic patients without




Fig. 2 Use of psychotropic drugs in patients in bipolar disorders treated with lithium (a, above) and in patients treated without lithium (b, below). The exact values per year for the figure can be found in the supplement material (supplementary tables). AD: Antidepressant drugs. AP: Antipsychotic drugs. TR: Tranquilizers. HYP: Hypnotics. Li: Lithium. AC: Anticonvulsant drugs

and with psychotic symptoms (F 31.1 versus F 31.2) shows an increase in antipsychotic use from about 70% to over 80% in mania without psychosis, while in psychotic mania antipsychotic use was about 80% over the whole period (supplementary Fig. S2 a, b).

Discussion

Our analysis of a large-scale pharmacoepidemiological dataset aimed to capture drug use patterns in inpatients with bipolar disorder in a network of hospitals in German-speaking countries over 24 years. Our focus here was also on drug use in patients with and without lithium. Our evidence aligns with trends from previous

Table 2 Rates (%) of the most common psychotropic (a) and somatic medications (b) in bipolar disorders without ($n = 5911$) and with lithium ($n = 2796$), 1994–2017

(a)				
Psychotropic medications	Without Lithium		With Lithium	
	n	%	n	%
Valproaic acid*	2261	38.25	449	16.06
Quetiapine*	1961	33.18	716	25.61
Lorazepam *	1270	21.49	513	18.35
Olanzapine	1058	17.90	478	17.10
Lamotrigine*	855	14.46	225	8.05
Venlafaxine	616	10.42	287	10.26
Mirtazapine	609	10.30	271	9.69
Risperidone	592	10.02	240	8.58
Diazepam	568	9.61	300	10.73
Carbamazepine*	531	8.98	133	4.76
Aripiprazole *	501	8.48	144	5.15
(b)				
Somatic medications	Without Lithium		With Lithium	
	n	%	n	%
Antihypertensive agents*	2081	35.20	763	27.30
Gastrointestinal agents*	1127	19.07	398	14.23
Thyroid therapeutics*	946	16.10	593	21.21
Analgetics/antirheumatics*	907	15.34	303	10.84
Diuretic agents*	628	10.62	188	6.72
Antidiabetic agents	550	9.30	215	7.69
Lipid-lowering agents	450	7.61	193	6.9
Vitamins	335	5.67	148	5.29
Laxatives	273	4.62	158	5.65
Anticoagulant drugs*	242	4.09	46	1.65

* $p < 0.001$

studies in patients with bipolar disorder from the USA, Taiwan, Denmark and other countries, reporting an essential increase of antipsychotics over the past years (Rhee et al. 2020; Kessing et al. 2016; Chiu et al. 2024). This increase was primarily driven by the consistently increasing prescription of SGAs, such as quetiapine, as observed in other cohorts (Rhee et al. 2020), whereas the use of first-generation antipsychotics gradually declined (Rhee et al. 2020; Chiu et al. 2024). We also found that the combined use of SGAs and lithium increased over the years in our cohort. It should be emphasized that SGAs are given at low doses such as quetiapine up to 100 mg/d and olanzapine up to 7.5 mg/d in about 20% of cases. Furthermore, antipsychotics were also administered in a high percentage of manic patients without psychotic symptoms. It has been previously suggested that the intensive marketing following the approval of SGAs may account for the substantial increase of prescriptions of SGAs in patients with bipolar disorder (Rhee et al. 2020). Initially prescribed off-label, SGAs were gradually approved for the treatment of bipolar disorder after demonstrating efficacy in bipolar depression. Because bipolar depression is considered difficult to treat, the efficacy of

SGAs in this indication may have further contributed to the increased use of SGAs in bipolar disorder (Rhee et al. 2020). Simultaneously, misconceptions regarding lithium's safety and the required blood monitoring protocols may have also led clinicians to favor SGAs over lithium (Fiorillo et al. 2023; Rhee et al. 2020).

In fact, in our cohort we observed a gradual decline of lithium use, which was relatively more pronounced in patients with manic episodes. The decline of lithium prescriptions has been also reported in other countries (Rhee et al. 2020; Kessing et al. 2016; Lyall et al. 2019; Lin et al. 2022). Regardless of the reasons behind the replacement of lithium with SGAs in the treatment bipolar disorder, it remains difficult to predict whether the declining use of lithium will eventually subside (Rhee et al. 2020; Parabiaghi et al. 2015; Shafiq et al. 2023). However, as clinicians gain more experience with SGAs in treatment of bipolar disorder (Koistinaho et al. 2023), it is unlikely that this trend will change in the near future. That the decline in lithium use ended after 2004 in our study is consistent with the findings of Kriner et al. 2024 (Kriner et al. 2024), who examined lithium use after 2014.

In our cohort, lithium-treated patients were, on average, treated with more drugs than patients without lithium. Polypharmacy is a common pattern in the treatment of patients with bipolar disorder (Rhee et al. 2020; Koistinaho et al. 2023). Moreover, patients treated with lithium may comprise a patient subgroup with a more complex illness course less responsive to pharmacotherapy; consequently, polypharmacy is a common treatment approach involving not only psychotropic, but also somatic drugs. For instance, the use of lithium in combination with other psychotropic drugs may suggest reluctance of clinicians to prescribe lithium unless all other options have been exhausted. The high frequency of use of antihypertensive drugs in combination with lithium and even more so in patients without lithium may be related to high rates of comorbidity and regular somatic monitoring in drug-treated bipolar patients (Nederlof et al. 2018). There may be several reasons for the high frequency of the combination with thyroid drugs; changes in thyroid function may be observed in patients with first-episode bipolar disorder, even in those not treated with lithium or quetiapine (Song et al. 2023). Moreover, thyroid hormone augmentation is used in treatment with bipolar disorder, in particular in treatment resistant depression, also in the absence of thyroid disease (Seshadri et al. 2022). Addition of thyroid hormones is common in lithium treatment to counteract latent hypothyroidism. Also, the risk of clinically relevant hypothyroidism in patients receiving long-term treatment with lithium has been previously reported (McKnight et al. 2012).

Another remarkable finding refers to the high rates of prescriptions of antidepressants, contrary to




Fig. 3 Use of psychotropic medications in 4,023 patients with depressive episodes (ICD-10 F31.3-5; a, above) and in 3,305 patients with manic episodes (ICD-10 F31.0-2; b, below). The exact values per year for the figure can be found in the supplement material (supplementary Tables 6 and 7). AD: Antidepressant drugs. AP: Antipsychotic drugs. TR: Tranquilizers. HYP: Hypnotics. Li: Lithium. AC: Anticonvulsant drugs

recommendations in guidelines, particularly in patients with bipolar depressive episodes, although a small decline was observed over the years. Clinicians should be aware of the risks related to antidepressant use in patients with bipolar disorder, such as manic switch (Jensen et al. 2023). In this context, the use of antidepressants in patients

without lithium was also worryingly high (between 66% and 91%), where lithium may have been co-prescribed to prevent a manic switch. Previous analyses of AMSP data have also observed a decrease in lithium and increase in valproate use in manic episodes (Kleimann et al. 2016; Wolfspurger et al. 2007), high antidepressants use

in bipolar depression (Greil et al. 2012; Haeberle et al. 2012), and polypharmacy in both poles of bipolar disorder (Kleimann et al. 2016; Wolfspurger et al. 2007; Greil et al. 2012; Haeberle et al. 2012). Using valproic acid in women aged 40 and younger was also acknowledged and criticized in an earlier AMSP paper (Kleimann et al. 2016).

Limitations

Several limitations should be considered when interpreting our findings. First, the lack of data concerning treatment outcomes, such as clinical response and/or safety does not allow any conclusions on effectiveness and tolerability of the prescribed drugs. Second, our pharmaco-epidemiological dataset only contains prescription data for inpatients; however, previous evidence suggests that the treatment setting, i.e., out- vs. inpatient (Al Jurdi et al. 2012), may have a relevant impact on prescription patterns given the major difference of clinical profiles of patients and thus we suggest caution when it comes to extrapolating our findings to the outpatient treatment. In fact, we may expect that use of lithium in the outpatient setting may be even more spectacularly declining than the trend we reported in inpatients in our study. Third, diagnoses were extracted from the medical records and therefore they may be less reliable compared to structured interviews. Finally, the dataset analyzed does not include specific clinical details of the cases, such as illness duration, hospitalization frequency or duration, suicidal tendencies, or family history. In addition to the large size of the data set, a further strength of the study is that prescriptions correspond to the actual use of the drugs, as the data is based on inpatients.

Conclusions

In this study, we assessed pharmacoepidemiological trends on the treatment of inpatients with bipolar disorder in a network of psychiatric hospitals in three European countries over a period of almost a quarter of century. We detected a consistently increasing use of SGAs, progressively replacing lithium. On the other hand, lithium appears to be frequently embedded in polypharmacy, suggesting that it is used in less responsive patients. The vanishing use of lithium in favor of SGAs and the persistently high rates of not recommended prescriptions of antidepressants have been previously reported in other parts of the world and call for action to reduce the gap between evidence-based recommendations and clinical practice.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40345-025-00370-1>.

Supplementary Material 1

Acknowledgements

The authors would like to thank all psychiatric hospitals participating in the AMSP project, in particular the drug monitors, for their continuous support in data collection.

Author contributions

W.G., M. de B. and G. Sch. initiated the study. G. Sch., W.G. and M.de B. wrote the main manuscript text. M.de B. conducted the statistical analyses and prepared figures and tables. N.N. undertook the literature research and designed tables and figures. R.B., A.E., R.G., G.H., N.N., J.S., and S.T. gave suggestions for improvement of the various versions of the manuscript. All authors proofread definite manuscript, reviewed and accepted the final version.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

No datasets were generated or analysed during the current study.

Author details

¹Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Zurich, Germany

²Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland

³Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland

⁴1st Department of Psychiatry and Psychotherapeutic Medicine, Klinik Hietzing, Vienna 1130, Austria

⁵Medical University of Vienna, Vienna, Austria

⁶Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland

⁷Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany

⁸The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA

⁹Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA

¹⁰Psychiatric Department, Ludwig Maximilian University Munich, Nussbaumstr. 7, D-80331 Munich, Germany

Received: 30 September 2024 / Accepted: 27 January 2025

Published online: 13 February 2025

References

- Al Jurdi RK, Schulberg HC, Greenberg RL, Kunik ME, Gildengers A, Sajatovic M, et al. Characteristics associated with inpatient versus outpatient status in older adults with bipolar disorder. *J Geriatr Psychiatry Neurol*. 2012;25(1):62–8.
- Antolin-Concha D, Lahtenvuo M, Vattulainen P, Tanskanen A, Taipale H, Vieta E, et al. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: a Finnish nationwide cohort study. *J Affect Disord*. 2020;277:885–92.
- Bridler R, Haberle A, Muller ST, Cattapan K, Grohmann R, Toto S, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. *Eur Neuropsychopharmacol*. 2015;25(6):763–72.
- Chiu HP, Shih Y, Lin CH. Fourteen-year trends in prescribing patterns for patients with bipolar mania discharged from a public psychiatric hospital in Taiwan. *Med (Baltim)*. 2024;103(9):e37270.
- Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, et al. The prevalence and burden of bipolar disorder: findings from the global burden of Disease Study 2013. *Bipolar Disord*. 2016;18(5):440–50.
- Fiorillo A, Sampogna G, Albert U, Maina G, Perugi G, Pompili M, et al. Facts and myths about the use of lithium for bipolar disorder in routine clinical practice: an expert consensus paper. *Ann Gen Psychiatry*. 2023;22(1):50.
- Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnesic mild

- cognitive impairment: randomised controlled trial. *Br J Psychiatry: J Mental Sci.* 2011;198(5):351–6.
- Glockner C, Grohmann R, Burkhardt G, Seifert J, Bleich S, Held T, et al. Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016. *J Neural Transm.* 2023;130(2):153–63.
- Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. *J Affect Disord.* 2012;136(3):534–42.
- Greil W, de Bardeci M, Muller-Oerlinghausen B, Nievergelt N, Stassen H, Hasler G, et al. Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data. *Int J Bipolar Disord.* 2023;11(1):34.
- Greil W, de Bardeci M, Nievergelt N, Toto S, Grohmann R, Seifert J et al. Twenty-three years of declining Lithium Use: analysis of a pharmacoepidemiological dataset from german-speaking countries. *Pharmacopsychiatry.* 2024.
- Grohmann R, Engel RR, Ruther E, Hippus H. The AMSP drug safety program: methods and global results. *Pharmacopsychiatry.* 2004;37(Suppl 1):S4–11.
- Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. *BMC Psychiatry.* 2012;12:153.
- Hidalgo-Mazzei D, Mantingh T, Perez de Mendiola X, Samalin L, Undurraga J, Strejilevich S, et al. Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders around the world: a survey from the ISBD Lithium task force. *Int J Bipolar Disord.* 2023;11(1):20.
- Jefsen OH, Rohde C, Ostergaard SD. Revisiting the association between treatment with antidepressants and mania: a nationwide within-individual study of 3554 patients with bipolar disorder. *Bipolar Disord.* 2023;25(7):583–91.
- Kessing LV. Why is lithium [not] the drug of choice for bipolar disorder? A controversy between science and clinical practice. *Int J Bipolar Disord.* 2024;12(1):3.
- Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. *Bipolar Disord.* 2016;18(2):174–82.
- Kleimann A, Schrader V, Stubner S, Greil W, Kahl KG, Bleich S, et al. Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study. *J Affect Disord.* 2016;191:164–71.
- Koistinaho A, Poranen J, Tanskanen A, Tiitonen J, Taipale H, Lahteenvuo M. Real-world use of pharmacological treatments for incident bipolar disorder: a Finnish nationwide cohort study. *J Affect Disord.* 2023;340:237–44.
- Kriner P, Brieger P, Pogarell O, Schule C, Musmann L, Korbacher J, et al. Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a bavarian drug surveillance project. *Front Psychiatry.* 2024;15:1425549.
- Lewitzka U, Severus E, Bauer R, Ritter P, Muller-Oerlinghausen B, Bauer M. The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review. *Int J Bipolar Disord.* 2015;3(1):32.
- Lin CH, Chan HY, Chen CC, Chou FH. Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006–2019. *J Affect Disord.* 2022;318:386–92.
- Lyall LM, Penades N, Smith DJ. *Br J psychiatry: J mental Sci.* 2019;215(1):415–21. Changes in prescribing for bipolar disorder between 2009 and 2016: national-level data linkage study in Scotland.
- Malhi GS, Bell E, Jadidi M, Gitlin M, Bauer M. Countering the declining use of lithium therapy: a call to arms. *Int J Bipolar Disord.* 2023;11(1):30.
- Mandal S, Mamidipalli SS, Mukherjee B, Hara SKH. Perspectives, attitude, and practice of lithium prescription among psychiatrists in India. *Indian J Psychiatry.* 2019;61(5):451–6.
- McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. *Lancet.* 2012;379(9817):721–8.
- Monteith S, Glenn T, Bauer R, Conell J, Bauer M. Availability of prescription drugs for bipolar disorder at online pharmacies. *J Affect Disord.* 2016;193:59–65.
- Nederlof M, Heerdink ER, Egberts ACG, Wilting I, Stoker LJ, Hoekstra R, et al. Monitoring of patients treated with lithium for bipolar disorder: an international survey. *Int J Bipolar Disord.* 2018;6(1):12.
- Parabiaghi A, Barbato A, Riso P, Fortino I, Bortolotti A, Merlino L, et al. Lithium use from 2000 to 2010 in Italy: a population-based study. *Pharmacopsychiatry.* 2015;48(3):89–94.
- Queissner R, Lenger M, Birner A, Dalkner N, Fellendorf F, Bengesser S, et al. The association between anti-inflammatory effects of long-term lithium treatment and illness course in bipolar disorder. *J Affect Disord.* 2020;281:228–34.
- Rhee TG, Olsson M, Nierenberg AA, Wilkinson ST. 20-Year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in Outpatient Care settings. *Am J Psychiatry.* 2020;177(8):706–15.
- Schoretsanis G, Paulzen M. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. *Mood stabilizers: Course and Duration of Therapy, Withdrawal syndromes, and resistance to Therapy.* *NeuroPsychopharmacotherapy Cham:* Springer; 2022.
- Schoretsanis G, de Filippis R, Brady BM, Homan P, Suppes T, Kane JM. Prevalence of impaired kidney function in patients with long-term lithium treatment: a systematic review and meta-analysis. *Bipolar Disord.* 2022;24(3):264–74.
- Seifert J, Maier HB, Fuhrmann F, Bleich S, Stubner S, Sieberer M, et al. Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001–2017. *J Neural Transm.* 2022;129(7):925–44.
- Seshadri A, Sundaresh V, Prokop LJ, Singh B. Thyroid hormone augmentation for bipolar disorder: a systematic review. *Brain Sci.* 2022;12(11).
- Shafiq S, Ronksley PE, Scory TD, Elliott MJ, Bulloch AGM, Patten SB. Ten-year trends in Lithium Prescribing in Alberta, Canada. *Can J Psychiatry Revue canadienne de psychiatrie.* 2023;7067437231176905.
- Shah N, Grover S, Rao GP. Clinical practice guidelines for management of bipolar disorder. *Indian J Psychiatry.* 2017;59(Suppl 1):S51–66.
- Shuy YK, Santharan S, Chew QH, Sim K. International trends in Lithium Use for Pharmacotherapy and Clinical correlates in bipolar disorder: a scoping review. *Brain Sci.* 2024;14(1).
- Song X, Feng Y, Yi L, Zhong B, Li Y. Changes in thyroid function levels in female patients with first-episode bipolar disorder. *Front Psychiatry.* 2023;14:1185943.
- Wolfsperger M, Greil W, Rossler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. *J Affect Disord.* 2007;99(1–3):9–17.
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord.* 2018;20(2):97–170.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.